Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan Menter

Showing results (191-200 of 298) with videos related to

Pageof 30
Sort By:
Journal of the American Academy of Dermatology|June 14, 2002
A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar linesJ Alastair Carruthers, Nicholas J Lowe, M Alan Menter, et al.
American Journal of Clinical Dermatology|September 8, 2019
Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II StudyMark G Lebwohl, Andrew Blauvelt, Alan Menter, et al.
Journal of the American Academy of Dermatology|March 12, 2010
The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trialAlan Menter, Matthias Augustin, James Signorovitch, et al.
Journal of the American Academy of Dermatology|January 3, 2015
Efficacy and safety of brodalumab in subpopulations of patients with difficult-to-treat moderate-to-severe plaque psoriasisKim Papp, Alan Menter, Bruce Strober, et al.
Lancet (London, England)|February 17, 2009
Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trialAlice Gottlieb, Alan Menter, Alan Mendelsohn, et al.
Journal of the American Academy of Dermatology|October 15, 2017
Spectrum of orocutaneous disease associations: Immune-mediated conditionsJeffrey D Cizenski, Pablo Michel, Ian T Watson, et al.
Journal of the American Academy of Dermatology|October 15, 2014
Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatmentKim Papp, Craig Leonardi, Alan Menter, et al.
Dermatology and Therapy|May 19, 2022
Symptom Experience and Content Validity of the Psoriasis Symptom Scale (PSS) in Patients with Generalized Pustular Psoriasis (GPP)A David Burden, Ulrich Mrowietz, Anne M Skalicky, et al.
Dermatologic Clinics|January 31, 2012
Quality-of-life instruments: evaluation of the impact of psoriasis on patientsMisha M Heller, Jillian W Wong, Tien V Nguyen, et al.
Journal of the American Academy of Dermatology|July 21, 2015
Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasisAlan Menter, Diamant Thaçi, Kim A Papp, et al.
Pageof 30

Showing results (191-200 of 298) with videos related to

Sort By:
Pageof 30
Journal of the American Academy of Dermatology|June 14, 2002
A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar linesJ Alastair Carruthers, Nicholas J Lowe, M Alan Menter, et al.
American Journal of Clinical Dermatology|September 8, 2019
Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II StudyMark G Lebwohl, Andrew Blauvelt, Alan Menter, et al.
Journal of the American Academy of Dermatology|March 12, 2010
The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trialAlan Menter, Matthias Augustin, James Signorovitch, et al.
Journal of the American Academy of Dermatology|January 3, 2015
Efficacy and safety of brodalumab in subpopulations of patients with difficult-to-treat moderate-to-severe plaque psoriasisKim Papp, Alan Menter, Bruce Strober, et al.
Lancet (London, England)|February 17, 2009
Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trialAlice Gottlieb, Alan Menter, Alan Mendelsohn, et al.
Journal of the American Academy of Dermatology|October 15, 2017
Spectrum of orocutaneous disease associations: Immune-mediated conditionsJeffrey D Cizenski, Pablo Michel, Ian T Watson, et al.
Journal of the American Academy of Dermatology|October 15, 2014
Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatmentKim Papp, Craig Leonardi, Alan Menter, et al.
Dermatology and Therapy|May 19, 2022
Symptom Experience and Content Validity of the Psoriasis Symptom Scale (PSS) in Patients with Generalized Pustular Psoriasis (GPP)A David Burden, Ulrich Mrowietz, Anne M Skalicky, et al.
Dermatologic Clinics|January 31, 2012
Quality-of-life instruments: evaluation of the impact of psoriasis on patientsMisha M Heller, Jillian W Wong, Tien V Nguyen, et al.
Journal of the American Academy of Dermatology|July 21, 2015
Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasisAlan Menter, Diamant Thaçi, Kim A Papp, et al.
Pageof 30